Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The triple therapy darunavir/r + tenofovir/emtricitabine is likely to become a relevant
first-line treatment option in the years to come. The dual combination of boosted darunavir +
raltegravir is an innovative treatment option that combines two potent new antiretroviral
drugs, one of which belongs to a new drug class (integrase inhibitor). The expected efficacy
profile of this combination is promising. Moreover, this combination might have a better
tolerance profile and has the advantage of sparing the NRTI class.
In the context of tenofovir/emtricitabine currently being a reference backbone in first-line
antiretroviral regimens, we hypothesise that, in combination with darunavir/r, raltegravir
may be an alternative option if its efficacy is non-inferior to tenofovir/emtricitabine.
Phase:
Phase 3
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)